1044 related articles for article (PubMed ID: 32231672)
1. The Red Blood Cell-Inflammation Vicious Circle in Sickle Cell Disease.
Nader E; Romana M; Connes P
Front Immunol; 2020; 11():454. PubMed ID: 32231672
[TBL] [Abstract][Full Text] [Related]
2. Vascular pathophysiology of sickle cell disease.
Connes P; Renoux C; Joly P; Nader E
Presse Med; 2023 Dec; 52(4):104202. PubMed ID: 37944640
[TBL] [Abstract][Full Text] [Related]
3. Vasculopathy and pulmonary hypertension in sickle cell disease.
Potoka KP; Gladwin MT
Am J Physiol Lung Cell Mol Physiol; 2015 Feb; 308(4):L314-24. PubMed ID: 25398989
[TBL] [Abstract][Full Text] [Related]
4. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction.
Nader E; Conran N; Romana M; Connes P
Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry.
Rab MAE; van Oirschot BA; Bos J; Kanne CK; Sheehan VA; van Beers EJ; van Wijk R
J Vis Exp; 2019 Nov; (153):. PubMed ID: 31762454
[TBL] [Abstract][Full Text] [Related]
6. Erythrocyte and plasma oxidative stress appears to be compensated in patients with sickle cell disease during a period of relative health, despite the presence of known oxidative agents.
Detterich JA; Liu H; Suriany S; Kato RM; Chalacheva P; Tedla B; Shah PM; Khoo MC; Wood JC; Coates TD; Milne GL; Oh JY; Patel RP; Forman HJ
Free Radic Biol Med; 2019 Sep; 141():408-415. PubMed ID: 31279092
[TBL] [Abstract][Full Text] [Related]
7. Blood rheology and vascular function in sickle cell trait and sickle cell disease: From pathophysiological mechanisms to clinical usefulness.
Connes P
Clin Hemorheol Microcirc; 2024; 86(1-2):9-27. PubMed ID: 38073384
[TBL] [Abstract][Full Text] [Related]
8. Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease.
George A; Pushkaran S; Konstantinidis DG; Koochaki S; Malik P; Mohandas N; Zheng Y; Joiner CH; Kalfa TA
Blood; 2013 Mar; 121(11):2099-107. PubMed ID: 23349388
[TBL] [Abstract][Full Text] [Related]
9. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.
Nyffenegger N; Zennadi R; Kalleda N; Flace A; Ingoglia G; Buzzi RM; Doucerain C; Buehler PW; Schaer DJ; Dürrenberger F; Manolova V
Blood; 2022 Aug; 140(7):769-781. PubMed ID: 35714304
[TBL] [Abstract][Full Text] [Related]
10. Association Between Nitric Oxide, Oxidative Stress, Eryptosis, Red Blood Cell Microparticles, and Vascular Function in Sickle Cell Anemia.
Nader E; Romana M; Guillot N; Fort R; Stauffer E; Lemonne N; Garnier Y; Skinner SC; Etienne-Julan M; Robert M; Gauthier A; Cannas G; Antoine-Jonville S; Tressières B; Hardy-Dessources MD; Bertrand Y; Martin C; Renoux C; Joly P; Grau M; Connes P
Front Immunol; 2020; 11():551441. PubMed ID: 33250889
[TBL] [Abstract][Full Text] [Related]
11. Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients.
Rab MAE; van Oirschot BA; Bos J; Merkx TH; van Wesel ACW; Abdulmalik O; Safo MK; Versluijs BA; Houwing ME; Cnossen MH; Riedl J; Schutgens REG; Pasterkamp G; Bartels M; van Beers EJ; van Wijk R
Am J Hematol; 2019 May; 94(5):575-584. PubMed ID: 30784099
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Vesicles in Sickle Cell Disease: Plasma Concentration, Blood Cell Types Origin Distribution and Biological Properties.
Nader E; Garnier Y; Connes P; Romana M
Front Med (Lausanne); 2021; 8():728693. PubMed ID: 34490315
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress in sickle cell disease; more than a DAMP squib.
van Beers EJ; van Wijk R
Clin Hemorheol Microcirc; 2018; 68(2-3):239-250. PubMed ID: 29614635
[TBL] [Abstract][Full Text] [Related]
14. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
[TBL] [Abstract][Full Text] [Related]
15. Reticulocyte mitochondrial retention increases reactive oxygen species and oxygen consumption in mouse models of sickle cell disease and phlebotomy-induced anemia.
Gallivan A; Alejandro M; Kanu A; Zekaryas N; Horneman H; Hong LK; Vinchinsky E; Lavelle D; Diamond AM; Molokie RE; Ramasamy J; Rivers A
Exp Hematol; 2023 Jun; 122():55-62. PubMed ID: 36934777
[TBL] [Abstract][Full Text] [Related]
16. Hypercoagulability in Sickle Cell Disease: A Thrombo-Inflammatory Mechanism.
Hamali HA
Hemoglobin; 2023 Nov; 47(6):205-214. PubMed ID: 38189099
[TBL] [Abstract][Full Text] [Related]
17. Oxidative pathways in the sickle cell and beyond.
Alayash AI
Blood Cells Mol Dis; 2018 May; 70():78-86. PubMed ID: 28554826
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities.
Alramadhani D; Aljahdali AS; Abdulmalik O; Pierce BD; Safo MK
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806451
[TBL] [Abstract][Full Text] [Related]
19. GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model.
Dufu K; Alt C; Strutt S; Partridge J; Tang T; Siu V; Liao-Zou H; Rademacher P; Williams AT; Muller CR; Geng X; Pochron MP; Dang AN; Cabrales P; Li Z; Oksenberg D; Cathers BE
Br J Haematol; 2023 Jul; 202(1):173-183. PubMed ID: 36960712
[TBL] [Abstract][Full Text] [Related]
20. Role of Macrophages in Sickle Cell Disease Erythrophagocytosis and Erythropoiesis.
Sesti-Costa R; Costa FF; Conran N
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
